Skip to end of metadata
Go to start of metadata


Living entities process information in very different ways than existing human-made objects, the former excel at having a built-in capability for self-reproduction, self-construction, evolvability, self-organization scalability, adaptability and robustness. We propose using evolving living technologies as a kind of analog computer that combines the computation of molecular interactions in living cells with the programmable manufacturing of molecules. We will create a prototype general-purpose programmable evolution machine able to create designer biomolecules with target activities by using as input: i) A (new type of) computer program specifying the instructions needed to build a new biomolecule with given properties and ii) Raw materials (e.g. chemical consumables, cell lines, etc). It will then compile this program, execute it and hence transform the raw materials and, as output, will produce the new biomolecule intended. This way, just as conventional computers are programmed to carry out arithmetic or logical operations on variables, our device will be programmed to carry out logical operations inside living cells using DNA as a variable. To design functional molecules we use re-engineered bacteriophages (phages) replicating in bioreactors filled with mixed bacterial populations. The mixing protocols are mapped to computational optimization algorithms. Despite recent advances in in vivo directed evolution techniques and the interest they have attracted so far, their impact in applied biotechnology is limited because of their limitations in programmability, selective drivers, cost and scalability.




The construction of a general-purpose programmable evolution machine to evolve biomolecules with new, or improved functions using phage particles. Our technology relies on living bacteria, phages and the principles of biological evolution to produce active biomolecules for health, biotechnology, and research. We aim to establish the foundations of such technology that is the amalgamation of (i) new programmable fluidic devices growing bacteria, (ii) phages that will produce novel biomolecules for biotechnology and medicine and (iii) state-of-the-art combinatorial evolution/selection algorithms that will be executed in living matter. The device we construct will use existing phage technology and synthetic regulation to engineer a programmable directed evolution machine able to produce biomolecules or biocomputational functionality faster than conventional techniques, whilst using fewer consumables.

At its core, phages are be subjected to combinatorial search algorithms exploiting the programmed mixing of engineered bacterial populations. Several phage populations can be further mixed to stimulate their recombination following protocols inspired from combinatorial optimization strategies. We are engineering novel genetic devices for phage engineering, mutation, recombination and selection. In addition, we are developing: i) fluidic modules for cell and phage growth, ii) their necessary hardware, iii) a custom instruction set architecture, and iv) high-level language with its own compiler. We will demonstrate the operation of our device by engineering biomolecules. We will also develop applications for a new type of distributed bacterial computing relying on the use of DNA as a signal. We will thus put in place the foundations and approaches for a living technology that will impact ICT as well as many areas beyond, such as biology, chemistry and manufacturing.




The Evoprog Consortium consisting of the international partners: University of Warwick (UK, the coordinator), Universidad Politecnica de Madrid (Spain), Imperial College (UK), CSIC (Spain), Universite d'Evry (France), and University of Glasgow (UK), works synergistically towards developments at biological, fluidic and computational layers, whilst keeping in mind that all the layers have be compatible for the integration to create an ultimate Evoprog machine.

The phage-assisted evolution system consists of: E. coli infectable with selection phages encoding the desired target gene to be evolved. After infection, only a protein or gene circuit with desired properties promotes an expression of a viral gene that is essential for infectious phage production. If such characteristics do not meet the programmed criteria, the essential gene is not expressed and such phages are eliminated from the system being diluted away from the bioreactor. We tested this system, and the protein with the desired properties has been selected after several rounds of reinfection.

We are constructing the following genetic devices:

  1. The development of a switchable expression platform to change its copy number and/or the net gene expression output under a transient pulse of a chemical inducer or a permanent pulse of a low-cost inducer (such as light or temperature).
  2. Design and implementation of mutation devices to increase genetic diversity to increase the speed of evolution.
  3. Implementation of phage and cell recombination during the phage-assisted evolution.
  4. Inducible genetic device for increasing mutation rates that is fundamental for fast evolution, has been developed. The mutagenesis platform consists of genes encoding specific enzymes that synergistically induce mutagenesis within the replicating genes.
  5. Programmable gene-specific mutagenesis. The partners have implemented a high precision programmable mutation system. This system allows programming specific mutagenesis within a gene of interest.

The consortium has been working synergistically on fluidic, hardware and biology layers, to integrate the i) molecular biology and multicellular computing levels (programmable genetic circuits, multi-sensing networks of logic gates) ii) bioprocess engineering (developing an integrated arrays of bioreactors for phages), iii) millifluidics (development of programmable switchable valves to operate programmable bioreactor arrays) and iv) the directed evolution system (operating the whole system). We undertake following steps towards the integration of the EVOPROG hardware with the biological layer:

  1. Developing the new multi-modular bioreactor system. The prototype of a new generation of multi-modular bioreactor system has been developed and sets of parameters across the bioreactors have been measured. The device aims to introduce a novelty and cost effective technological solution for extending the continuous culture of several microorganism in controllable conditions.
  2. Parallel evolution experiments in the new bioreactor system to test the system. The consortium been testing the new generation of the bioreactor system to establish the evolution scope in independent bioreactors. The run parameters during this parallelized experiment were consistent across the array of bioreactors. The success of the evolution is confirmed by an independent re-occurrence of mutations that fall into a cluster.
  3. Optimization of the phage for evolution experiments. To pre-optimize the phage genome for evolution experiments a parallelized run delivered new phages that they replicate at high rates in the presence of low amount of the conditionally expressed gene.
  4. Computation outside the cells. The EVOPROG machine can also implement programs where the computation takes place outside the cell, which does not rely on gene expression. This is done by re-engineering the phage adsorption.

The development of the fluidic processor involves designing, constructing and testing a 3D printed fluidic system for EVOPROG prototype. Collaborative engineering across the Evoprog consortium resulted in the 3D-printed systems that enable parallelized liquid handling for evolution experiment operated in the EVOPROG machine. Through our work, we have designed and agreed on a specification for a parallelized functional EVOPROG system. The currently tested system accommodates two phage reactors and 10 chemostat/turbidostat systems with E.coli cells carrying different types of genes for phage-assisted directed evolution. Specialized device for the system includes 3D printed 3-way and 6-way valve assembly for parallelization of fluid control. The valves have been tested for operation and software compatibility to confirm the correct operation when embedded in EVOPROG machine.



The critical achievement is the development of a high level programming language to perform automation through a particular physical layout, the EVOPROG machine for executing directed evolution protocols. In general, the software development has been progressing in the following context:

  1. Fact: the description of biology protocols (and in particular, directed evolution protocols) is usually ambiguous and incomplete.
  2. Problem: Many published protocols are executed manually and are not reproducible in other labs. It is beyond of the expertise of many biologists to design and run an array of multi-modular fluidic devices.
  3. Solution: A programming language for molecular biology protocols that is able to describe in a precise way the biological steps of a directed evolution experiment.

Advantages of the code include standardization and automation: a biology protocol described using a programming language is easily analysed for correctness and debugging and its execution can be automatized in a robotic/fluidic platform. This will ensure that the user (biologist/biotechnologist) can focus on the design and specification of the biological protocol and specifications of the desired outcome, whilst skipping all the details on running a directed evolution protocol on a fluidic array.




An ultimate test of our integration of hardware, software and biology will be the development of multi-sensing bacterial strains to respond in a pre-programmed way to multi-signal environment in bioreactors (multicellular computing). As a proof of concept a phage-based logic game is in the process of implementation to be operated in the EVOPROG machine.

In summary, the success of Evoprog consortium will bring an unparalleled machine integrating biology, fluidic hardware and software solutions to enable programming diverse evolution experiments. As result, novel biologicals for medicine, biotechnology and academia will be generated faster, with better reproducible outcome.

Our Evoprog machine is modular and allows to run complex biological experiments including directed evolution, targeted genome engineering, and many others.


Advanced 3D printing technology is essential for Evoprog hardware implementation

(a) CAD design of the T-junction device with one aqueous inputs, one oil input, and an output. Internal channel structures are illustrated in blue. Aqueous phase (indicated in blue in the inset) was introduced from the top inlet and oil phase (white) from the left. (b) The CAD design of 3D droplet generator. Aqueous phase (blue in the inset) was cut into small droplets by oil phase (white). (c) Microscopic pictures of generated droplets. Flow rates of aqueous phase are 0.4, 0.8, 1.6, and 2.4 ml/min (top to bot-tom). The top two images were from the 3D device, and the bottom ones were from the T-junction device. Scale bar: 250 µm. (d) Plot of droplet diameter as a function of the flow rate of aqueous phase. The flow rate of oil phase was fixed at 2.8 ml/min. Error bars were standard deviations.

(a) A schematic diagram of 3D printed micro cell culture system. Fresh growth media (red) are supplied to each cell culture vial every time readings from LED/photodiode sensor pair (corresponding to optical density (OD) of bacterial cell culture) exceed a threshold level(turbidostat operation). The system is parallelized using 6-way valve to distribute cell culture media to up to 6 culture vials. (b) A photograph of 3D printed micro continuous cell culture systems. The holders (black) for cell culture vials, which also works as LED/sensor holder, were printed in Connex500 3D printer (Stratasys).





  • None